Download Files:
Products Details
Product Description
– Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD)[1].
Web ID
– HY-141411A
Shipping
– Room temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C25H21ClF3N5O2S
References
– [1]Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127.
CAS Number
– 1998760-00-1
Molecular Weight
– 547.98
SMILES
– O=S(/N=C(N1N=C(C2=CC=C(Cl)C=C2)[C@@H](C3=CC=CC=C3)C1)/N=C(N)/C)(C4=CC=C(C(F)(F)F)C=C4)=O
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease
Solubility
– 10 mM in DMSO
Target
– Cannabinoid Receptor;NO Synthase
Isoform
– CB1
Pathway
– GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
